Thapar, A
,
Martin, J
Mick, E
Arias Vásquez, A
Langley, K
Scherer, S W
Schachar, R
Crosbie, J
Williams, N
Franke, B
Elia, J
Glessner, J
Hakonarson, H
Owen, M J
Faraone, S V
O'Donovan, M C
Holmans, P
Article History
Received: 2 April 2015
Revised: 8 July 2015
Accepted: 8 September 2015
First Online: 17 November 2015
Competing interests
: Dr R Schachar has served as an advisor or consultant to Eli Lilly, Purdue Pharma and Highland Therapeutics and is named on institutional patents for several genes involved in ADHD and for a stop-task software programme. Dr SV Faraone has received research support from, served as consultant or adviser to or participated in CME programmes sponsored by Alcobra, Janssen, Eli Lilly, NIH, Novartis, McNeil, Pfizer and Shire; he receives royalties from Guilford Press and Oxford University Press. In the past year, Dr SV Faraone received income, potential income, travel expenses and/or research support from Pfizer, Ironshore, Shire, Akili Interactive Labs, CogCubed, Alcobra, VAYA Pharma, Neurovance, Impax and NeuroLifeSciences. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. The remaining authors declare no conflict of interest.